Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 15,000 shares, a drop of 14.3% from the November 15th total of 17,500 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.3 days.
Institutional Investors Weigh In On Comera Life Sciences
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new position in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 202,000 shares of the company's stock, valued at approximately $29,000.
Get Comera Life Sciences alerts:Comera Life Sciences Stock Performance
NASDAQ CMRAW remained flat at $0.06 during mid-day trading on Friday. The company's stock had a trading volume of 3 shares, compared to its average volume of 165,797. Comera Life Sciences has a 12-month low of $0.03 and a 12-month high of $0.70. The firm's fifty day moving average price is $0.06.
About Comera Life Sciences
(Get Rating)Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
See Also
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.